Browsing Tag
chronic rhinosinusitis
5 posts
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?
What makes Aptar Pharma’s latest nasal drug delivery bet a potential market disruptor?
Aptar Pharma teams up with Dianosic to advance a bioresorbable nasal scaffold platform for chronic sinus and rhinitis care. Find out how this could reshape treatment.
FDA refuses to approve AstraZeneca’s sBLA for Fasenra in CRSwNP
The US Food and Drug Administration (FDA) has refused to approve the supplemental biologics license application (sBLA) of…
Medtronic to acquire ENT medical technology company Intersect ENT
Irish medical device company Medtronic has agreed to acquire Intersect ENT, an ear, nose, and throat (ENT) medical…
Lyra Therapeutics raises $30m for chronic rhinosinusitis drug candidates
Lyra Therapeutics has raised $30 million in a Series C financing round to advance its lead product candidates…